Brexanolone - Sage Therapeutics

Drug Profile

Brexanolone - Sage Therapeutics

Alternative Names: SAGE-547; SGE-102

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sage Therapeutics
  • Developer SAGE Therapeutics
  • Class Antidepressants; Antiepileptic drugs; Small molecules; Steroids
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Status epilepticus
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Postnatal depression; Status epilepticus
  • Phase II Essential tremor
  • Preclinical Major depressive disorder

Most Recent Events

  • 09 Nov 2017 Sage intends to file a New Drug Application with the US FDA in 2018
  • 09 Nov 2017 Top-line efficacy and adverse events data from phase III Hummingbird programme released by Sage Therapeutics
  • 02 Nov 2017 Sage Therapeutics completes enrolment in its phase III trial for Postnatal depression in USA and New Zealand (NCT02942004)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top